<DOC>
	<DOCNO>NCT02799550</DOCNO>
	<brief_summary>The purpose study evaluate safety efficiency allogeneic cluster differentiation 19 ( CD19 ) -directed chimeric antigen receptor modify T cell ( CART-19 ) infusion patient relapse / refractory B-cell acute lymphoblastic leukemia ( B-ALL )</brief_summary>
	<brief_title>Allogeneic CART-19 Elderly Relapsed/Refractory CD19+ ALL</brief_title>
	<detailed_description>The relapsed and/or refractory B-ALL patient receive infusion allogeneic CART-19 within 1 week chemotherapy . The re-induction chemotherapy regimen primarily vindesine , mitoxantrone , cyclophosphamide , pegaspargase dexamethasone , graft-versus-host disease ( GVHD ) prevention conduct pre- post- therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>Age ≥ 60 year Patient relapse and/or refractory CD19 positive Bcell acute lymphoblastic leukemia ( BALL ) Estimated life expectancy ≥ 12 week ( accord investigator 's judgment ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Previous treatment investigational gene cell therapy medicine product CD19 negative Bcell leukemia Any uncontrolled active medical disorder would preclude participation outline</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CART</keyword>
	<keyword>ALL</keyword>
	<keyword>elderly</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>CD19+</keyword>
</DOC>